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Introduction
Bluetongue has a significant economic direct and indirect impacts (Saegerman et al., 2008). In September of 2015, an outbreak of BTV-8 was reported in
France. Due to the risk for re-introduction, preventive vaccination would enable Belgium to maintain its status of freedom from BTV-8 infection. To finance this
programme, both decision-makers and stakeholders need to be persuaded by the effectiveness and the cost-benefit of vaccination.
Methods
Effectiveness of livestock vaccination
The effects of vaccination on seronegative individual cattle before the vaccination programme (2007-2008 (WS2)) and during/after (2008-2009 (WS3)) were
analysed. Pearson and Spearman correlations were used between two relevant variables to identify variables of interests that were kept for a multivariate
model analysis.
Cost-Benefit analysis
The model developed by Velthuis (Velhuis et al., 2011) was adapted to the Belgian bovine and ovine population data. For infected herds, costs include impact
on production, preventive measures and treatment costs and trade restriction as described by Hanon (Hanon et al., 2009). The benefit is modelled as a
function of avoided cost linked to productivity loss, treatment, and preventive management costs (e.i. insect repellents, export losses).
Results
Effectiveness of livestock vaccination
Animals with a longer duration between first vaccine injection and sampling have a superior ‘Change’(= a variable obtained by subtracting QuantiWS2(=100 -
Optical Density sample/Optical Density negative kit control)*100) from QuantiWS3) than the others which highlights the efficiency of the vaccine to induce
antibodies. Having received two vaccine injections at sampling time also significantly increase ‘Change’ (Table I).
Table I. Results of the linear mixed model modelling the increase in serology between winterscreening 2008 (WS2) and winterscrening 2009 (WS3) (‘Change’)
This study evaluated the effectiveness of vaccination against BTV-8 in Belgium and has shown that the interaction between the time
since the first injection and the second injection of the primo-vaccination is significantly associated to the change in serology
showing vaccine efficiency induces antibodies production. This study also clearly confirms the benefit of vaccination by
reducing economic impact of treatment and production losses, especially in dairy cattle herds.
Variable Coefficient Standard Error P-value
Age 0.34 0.31 0.27
Time 27.69 10.01 <0.01
Two injections 52.01 11.28 <.0001
StatusWS1 8.05 6.42 0.21
Time*Two Injections -32.69 12.31 0.02
Injection*Age -0.57 0.35 0.11
‘Age’: Age of the cattle.
‘Time’: number of months between the date of first
injection at herd level and the sampling date of the
individual cattle.
‘Two injections’: indicates whether the animal had
received its second vaccination (=1) or not yet (=0) at
moment of sampling.
‘StatusWS1’: indicates whether the cattle came from a
herd where within-herd seroprevalence in WS1 was
above the mean prevalence of 27% or not.
Cost-Benefit analysis
The total net returns gained by avoiding compared to the vaccination cost was always positive at farm (Figure1) and at national level (Figure 
2) with the exception of fattening calves, due to their short lifetimes.
Figure 1: Expected cost of an epidemic in case no BTV-8 vaccination compared to vaccination cost at 
farm level for each defined herd category.
Figure  2: Expected cost of an epidemic in case no BTV-8 vaccination compared to vaccination cost 
at national level for each defined herd category.
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